Atopic Dermatitis Drugs Market Forecasts to 2030 - Global Analysis By Drug Class, Severity, Formulation, Route of Administration, Application and By Geography

According to Stratistics MRC, the Global Atopic Dermatitis Drugs Market is accounted for $13.62 billion in 2023 and is expected to reach $25.48 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Atopic Dermatitis Drugs refer to pharmaceuticals used to manage the symptoms of atopic dermatitis, a chronic inflammatory skin condition characterized by itching, redness, and rash. By addressing the underlying immune system dysfunction, these drugs help in controlling the disease progression and minimizing long-term complications. By controlling the disease progression and enhancing skin barrier function, atopic dermatitis drugs empower patients to better manage their condition, leading to improved overall well-being and productivity.

According to the World Health Organization (WHO), over 900 million people were affected with skin disease in 2017, and around 80% of the skin disorders are accounted for by the five common skin disorders. Atopic dermatitis, a common and chronic inflammatory skin disease, affects 15% to 20% of children and 1% to 3% of adults across the world.

Market Dynamics:

Driver:

Rising incidence of atopic dermatitis

With an increasing number of patients seeking treatment, there is a growing demand for effective pharmaceutical interventions. This surge in demand stimulates research and development efforts, leading to the introduction of innovative therapies. Moreover, the expanding patient pool creates a larger market opportunity for pharmaceutical companies, encouraging investment in drug development and marketing strategies. Consequently, the rising prevalence of atopic dermatitis directly fuels the growth of the atopic dermatitis drugs market.

Restraint:

Side effects and safety concerns

Side effects and safety concerns in atopic dermatitis drugs include immunosuppression, increased risk of infections, skin irritation, and allergic reactions. These adverse effects limit the widespread use of certain medications, impacting patient adherence and treatment outcomes. Moreover, safety issues raise regulatory scrutiny, prolonging approval processes and increasing development costs. High incidences of side effects also lead to patient dissatisfaction, reducing confidence in available treatments and hindering market growth.

Opportunity:

Rising healthcare expenditure

Rising healthcare expenditure enhances patient access to treatment options. With greater financial resources allocated to healthcare, individuals can afford expensive biologic drugs and novel therapies for atopic dermatitis. Moreover, increased healthcare spending often correlates with improved infrastructure, healthcare services, and patient education, leading to earlier diagnosis and treatment initiation. Overall, the uptrend in healthcare expenditure creates a conducive environment for market expansion and innovation in atopic dermatitis therapeutics.

Threat:

Generic competition

Generic competition in atopic dermatitis drugs arises when patents for branded medications expire, allowing generic drug manufacturers to produce and sell equivalent versions at lower prices. As a result, pharmaceutical companies face decreased profitability and reduced incentives for investing in research and development of innovative treatments. Additionally, generic competition limits patient access to newer, potentially more effective therapies, impacting overall market demand and growth.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the atopic dermatitis drugs market. Lockdowns and disruptions in healthcare services have led to delays in diagnosis and treatment initiation for atopic dermatitis patients. Additionally, economic uncertainties have reduced patient affordability and access to expensive biologic drugs. Clinical trials for new treatments have also faced delays, affecting pipeline progress. Overall, the market has experienced a mix of challenges and opportunities, with long-term implications for growth and innovation.

The tablets segment is expected to be the largest during the forecast period

The tablets segment is estimated to have a lucrative growth. Atopic dermatitis, a chronic inflammatory skin condition, is often managed through oral medications in tablet form. These drugs aim to alleviate symptoms such as itching, inflammation, and rash associated with the condition. They offer systemic relief, targeting inflammation from within, which can be particularly effective for widespread or severe cases of atopic dermatitis. These tablets are part of a comprehensive approach to managing atopic dermatitis, often combined with topical treatments and lifestyle modifications.

The inflammation segment is expected to have the highest CAGR during the forecast period

The inflammation segment is anticipated to witness the highest CAGR growth during the forecast period. Atopic dermatitis, a chronic inflammatory skin condition, sees several drug interventions targeting inflammation. By modulating immune responses and reducing inflammation, they can prevent disease flare-ups and promote long-term remission. Overall, their efficacy in controlling inflammation not only relieves discomfort but also mitigates the risk of complications associated with chronic atopic dermatitis.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period due to rising prevalence, increasing healthcare expenditure, and expanding awareness about the condition. Countries like Japan, China, and South Korea are key contributors to market expansion due to their large patient populations and improving access to healthcare. Additionally, partnerships between pharmaceutical companies and local healthcare providers facilitate market penetration. Overall, the Asia-Pacific Atopic Dermatitis Drugs Market is poised for continued expansion fuelled by evolving healthcare infrastructure and growing patient awareness.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to high prevalence of atopic dermatitis, sophisticated healthcare infrastructure, and significant investments in research and development. The United States dominates the market, with a significant portion of revenue attributed to biologic drugs and topical corticosteroids. Further, the region's well-established pharmaceutical industry and strong regulatory framework support the development and commercialization of innovative therapies.

Key players in the market

Some of the key players profiled in the Atopic Dermatitis Drugs Market include Sanofi, Regeneron Pharmaceuticals, Pfizer Inc., Novartis AG, Eli Lilly and Company, AbbVie Inc., Astellas Pharma Inc., LEO Pharma A/S, Galderma S.A., Johnson & Johnson, Bristol Myers Squibb, AnaptysBio Inc., Encore Dermatology Inc., GlaxoSmithKline PLC, AstraZeneca PLC and Glenmark Pharmaceuticals.

Key Developments:

In January 2024, Pfizer and Glenmark Pharmaceuticals announced that they had collaborated to launch abrocitinib, an oral treatment for moderate-to-severe atopic dermatitis (AD) in India. Pfizer developed abrocitinib, which has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO). Glenmark and Pfizer will co-market the product under the brand names Jabryus and Cibinqo, respectively.

In January 2024, Sanofi's Dupixent (dupilumab) has been approved for use in treating moderate to severe atopic dermatitis in patients aged 12 and older in the European Union. It is also the first and only biologic medicine in India that has shown improved disease signs, symptoms, and quality of life measures for atopic dermatitis.

Drug Classes Covered:

• Corticosteroids
• Calcineurin Inhibitors
• Systemic Immunosuppressants
• Phosphodiesterase-4 (PDE4) Inhibitors
• Antihistamines
• Other Drug Classes

Severities Covered:

• Mild
• Moderate
• Severe

Formulations Covered:

• Tablets
• Lotions
• Syrups
• Sprays
• Other Formulations

Route of Administrations Covered:

• Topical Drugs
• Oral Drugs
• Injectable Drugs

Applications Covered:

• Phototherapy
• Immunomodulation
• Infection Prevention
• Skin Barrier Dysfunction
• Inflammation
• Itching
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances